Based on the data from this study, we demonstrated that the RNA-binding protein STAU2 is a useful regulator of PAAD initiation and progression, suggesting that targeting RBPs is a promising therapeutic strategy for patients with PAAD. This evidence concerns the gene STAU2 and pancreatic adenocarcinoma.